Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1995-06-06
2000-07-18
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241981, 514 15, 530300, 530328, 530395, 530403, 530868, 530402, C07K 706, C07K 1444
Patent
active
060903872
ABSTRACT:
The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens completed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides specific .beta.-chain variable regions of T cell receptors, designated V.beta.3, V.beta.4, V.beta.12, V.beta.14 and V.beta.17, which are associated with the pathogenesis of autoimmune diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). Also provided are means to detect, prevent and treat RA and MS. Methods of administering DNA or RNA encoding the polypeptides useful as vaccines of the present invention into the tissue cells of an individual is also provided.
REFERENCES:
patent: 4886743 (1989-12-01), Hood et al.
patent: 5151262 (1992-09-01), Babiuk et al.
patent: 5223426 (1993-06-01), Skibbons et al.
patent: 5436319 (1995-07-01), Kung et al.
patent: 5612035 (1997-03-01), Howell et al.
patent: 5614192 (1997-03-01), Vandenbark et al.
Tanuma et al Cell. Immunol. 168:85-90, 1996.
Giegerich et al. Eur. J. Immunol. 22:753-758, 1992.
Bourdette et al J. of Immunol. 152: 2510-2518 1994.
Bernards et al PNAS 84: 6854-6858 1987.
Hafler et al. Immunology Today 17:152 1996.
Kumar et al PNAS 87:1337, 1990.
Abe et al., Proc. Natl. Acad. Sci. USA 89:4066-4070 (1992).
Acha-Orbea et al., "Limited heterogeneity of T cell receptors from lymphocytes mediatinng autoimmune encephalomyelitis allows specific immune intervention." Cell 54: 263-273 (1988).
Ben-Nun et al., "Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein." Nature 292:60-61 (1981).
Biddison et al., "The germline repertoire of T-cell receptor beta-chain genes in patients with multiple sclerosis." Res. Immunol. 140:212-215 (1989).
Brostoff et al., "T Cell receptors, immunoregulation, and autoimmunity." Clinical Immunology and Immunopathology 62:1-7 (1992).
Brostoff et al., Immunol. Ser. 59:203-218 (1993).
Burns et al., Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar V .alpha. and V .beta. chain genes even though the major histocompatibility complex of encephalitogenic determinants being recognized are different. J. Exp. Med. 169:27-39 (1989).
Choi et al., "Interaction of Staphylococcus aureus toxins "superantigens" with human T cells." Proc. Natl. Acad. Sci. USA 86:8941-8945 (1989).
Chluba et al., "T cell receptor .beta. chain usage in myelin basic protein-specific rat T lymphocytes." Eur. J. Immunol. 19:279-284 (1989).
Choi et al., Proc. Natl. Acad. Sci. USA 88:8357 (1991).
Clark et al., Ann. Neurol. 31:587-592 (1992).
Cohen and Weiner, Immunol. Today 9:332-335 (1988).
Edouard et al., Eur. J. Immunol. 23:727-733 (1993).
Esch et al., Crit. Rev. Immunol. 11(5):249-264 (1992).
Gaur et al., Science 259:91-93 (1991).
Gregorian et al., FASEB J. 6:A1685 (1992).
Grunewald et al., Eur. J. Immunol. 22:129-135 (1992).
Grunewald et al., Scand. J. Immunol. 34:161-168 (1992).
Howell et al., Proc. Natl. Acad. Sci. USA 88:10921-10925 (1991).
Howell et al., "Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides." Science 246:668-670 (1989).
Infante et al., J. Immunol. 148:3385-3390 (1992).
Janeway, C., "Self superantigens?" Cell 63:659-661 (1990).
Kawano et al., Cancer Eye Res. 10:789-795 (1991).
Kimura et al., Sequences and repertoire of the human T cell receptor .alpha. and .beta. chain variable region genes in thymocytes. Eur. J. Immunol. 17:375-383 (1987).
Lahesmaa et al., J. Immunol. 150:4125-4135 (1993).
Lee et al., Ann. Neurol. 29:33-40 (1991).
Lider et al., "Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis." Science 239:181-183 (1988).
Lohse et al., Science 244:820-822 (1988).
Marrack and Kappler, "The staphylococcal enterotoxins and their relatives." Science 248:705-711 (1990).
Offner et al., "Lymphocyte vaccination against experimental autoimmune encephalomyelitis: evaluation of vaccination protocols." J. Neuroimmunol. 21:13-22 (1989).
Owhashi and Heber-Katz, "Protection from experimental allergic encephalomyelitis conferred by a monoclonal antibody directed against a shared idiotype on rat T cell receptors specific for myelin basic protein." J. Exp. Med. 168:2153-2164 (1988).
Paliard et al., Science 253:325-329 (1991).
Patten et al., "Structure, expression and divergence of T-cell receptor .beta.-chain variable regions." Nature 312:40-46 (1984).
Posnett et al., J. Clin. Invest. 85:1770-1776 (1990).
Pullen et al., "Identification of the region of T cell receptor B chain that interacts with the self-superantigen Mis-1.sup.a." Cell 61:1365-1374 (1990).
Ross et al., "Antibodies to synthetic peptides corresponding to variable-region first-framework segments of T cell receptors." Immunol. Res. 8:81-97 (1989).
Schluter et al., "Antibodies to synthetic joining segment peptide of the T-cell receptor .beta.-chain: serological cross-reaction between products of T-cell receptor genes, antigen binding T-cell receptors and immunoglobulins." Chem. Abstracts 105(1):464, asbstract No. 4767q (1986).
Sedgwick, J. "Long-term depletion of CD8 T cells in vivo in the rat: no osberved role for CD8 (cytotoxic/suppressor) cells in the immunoregulation of experimental allergic encephalomyelitis." Eur. J. Immunol. 18:495-502 (1988).
Sellins et al., J. Immunol. 149:2323-2327 (1992).
Smith et al., Blood 81:1521-1526 (1993).
Sun et al., "Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions." Nature 332:843-845 (1988).
Urban et al., "Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy." Cell 54:577-592 (1988).
Vandenbark et al., "Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmun encephalomyelitis." Nature 341:541-544 (1989).
White et al., "The V.beta.-specific superantigen staphylococcal enterotooxin B: stimulation of mature T cells and clonal deletion in enonatal mice." Cell 56:27-35 (1989).
Wucherpfennig et al., "Shared human T cell receptor V.beta. usage to immunodominant regions of myelin basic pprotein." Science 248:1016-1019 (1990).
Yanagi et al., "A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains." Nature 308:145-149 (1984).
Zamvil et al., "Predominant expression of a T cell receptor V.sub..beta. gene subfamily in autoimmune encephalomyelitis," J. Exp. Med. 167:1586-1596 (1988).
Brostoff Steven W.
Carlo Dennis J.
Howell Mark D.
Chan Christina Y.
Lubet Martha
The Immune Response Corporation
LandOfFree
Vaccination and methods against diseases resulting from pathogen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccination and methods against diseases resulting from pathogen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccination and methods against diseases resulting from pathogen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2033769